This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
New Board members to our charity
Alpha-1 Awareness is a charity founded and run by volunteers to help bring awareness of AATD as well as give support to those
Alpha-1 Awareness donate £10,000 to the research of a cure
Alan Wooler, David Lomas & Emma Wooler On Monday 3rd February 2020, Alan and Emma Wooler of Alpha-1 Awareness went to UCL
New promotion, New Board Member and New website!
We at Alpha-1 Awareness have some wonderful news that we would like to share with you. Internal Promotion Glyn Cockaday joined our charity
Non-profit Group grants Richland girl’s American Ninja Warrior wish
RICHLAND, WA- The Wishing Star Foundation is a non-profit based out of Spokane that grants the wishes of children ages 3-21 with terminal, life threatening
RCSI team to start trial for promising Covid-19 therapy for severe infections
Researchers in Ireland are hoping to add to the growing list of drug candidates for the treatment of patients with severe Covid-19 infection.
Double-lung transplant patient and father of three survives COVID-19
MOUNT PLEASANT (WJRT) (4/21/2020) – At 37, Paul DeWyse was diagnosed with a rare disease called alpha 1 antitrypsin deficiency. “Basically that is your
AlphaNet Announces New Appointment to the Board of Directors
AlphaNet is pleased to announce the appointment of Dell Witcher to the board of directors, effective May 14, 2020. “Dell’s expertise and involvement
Research Priorities in Alpha-1 antitrypsin deficiency (AATD)
We need your help! Being led by the European Alpha-1 Research Collaboration (EARCO), a survey has been created to give us all input
CSL Behring employees ride with Alpha-1 Foundation Team for Escape to the Cape.
Two dozen CSL Behring employees are pedaling the highways and byways of Cape Cod, Massachusetts, this weekend as part of the Alpha 1
Largest Source of AATD Stem Cells Collected
Researchers from the Center for Regenerative Medicine (CReM) have assembled the largest repository of patient derived stem cells (iPSCs) from patients with alpha-1
Researchers build a better lung model
(Boston)–Using a combination of pluripotent stem cells (cells that can potentially produce any cell or tissue type) and machine learning (artificial intelligence that
Research Priorities in Alpha-1 antitrypsin deficiency (AATD)
We need your help! Being led by the European Alpha-1 Research Collaboration (EARCO), a survey has been created to give us all input
First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency
Z Factor Ltd, a Cambridge-based drug development company spun out of the University of Cambridge, announced that the first human volunteer was dosed
Arrowhead Pharmaceuticals: Pushing the Boundaries of Gene Silencing
RNA interference (RNAi), sometimes called gene silencing, is an approach to therapeutics in certain diseases that are caused by the production of abnormal
Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
LEXINGTON, Mass.–(BUSINESS WIRE)–Dec. 17, 2019– Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced
Danish Medicines Council Grants Approval for CSL Behring’s Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients
HATTERSHEIM AM MAIN, Germany, Jan. 24, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision,
CSL Behring lift their precautionary distribution hold on ZEMAIRA®
The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of
Diplomat signs exclusive practice-based infusion agreement with Allergy Partners
FLINT, Mich., Aug. 8, 2019 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), is pleased to announce an exclusive agreement between Diplomat and Allergy Partners, P.A., to manage in-office
European Lung Foundation advise on planning a flight
ELF (European Lung Foundation) has produced a poster to help make people with lung conditions aware of the steps they should take when
Health Benefits of Air Pollution Reduction
Reducing air pollution improves people’s health very quickly, reports a paper from the Forum of International Respiratory Societies (FIRS). Air pollution is when
Michigan becomes first state to ban flavored e-cigarettes
Michigan becomes the first state to ban flavored e-cigarettes for minors starting today. Governor Gretchen Whitmer has been making a push to get nicotine out
First U.S. death caused by vaping confirmed in Illinois
The first reported death tied to vaping in the United States was confirmed on Friday by officials from the Illinois Department of Public Health.